Greater China News
估值超8.29亿美元！宜明昂科港股过聆讯
“8月14日，宜明昂科港股上市正式通过聆讯，预计不久后将成为今年少有的biotech上市股。中金公司和摩根士丹利担任联席保荐人。（关注公众号后台回复“宜明昂科”获取招股书PDF） 宜明昂科核心产品IMM0306（CD47×CD20）、IMM2902（CD47×HER2）及IMM2520（CD47×PD-L1）均为三个基于CD47的双特异性分子。其他10款处于不同开发阶段可靶向关键先天及适应性免疫靶点的候选药物，包括CD24抗体、CD47×CD24双抗、PD-L1×CD24双抗及3款处于临床及IND阶段的适应性免疫药物（VEGF×PD-L1双抗、CTLA-4 ADCC增强型单抗、CD70单抗），其他先天免疫检查点早期靶点包括IL-8抗体、NKG2A抗体、PSGL-1抗体。 近年来除CD47外，宜明昂科还选择并验证了另一个先天免疫检查点CD24。正在围绕CD24开发一款处于IND准备阶段及多款发现阶段及临床前阶段的候选药物，每一款都有可能成为同类中最早进入临床阶段的全球少数首创药物。2022年Pheast Therapeutics完成7600万美元A轮融资。融资由ARCH和Catalio Capital Management领投。这家临床前公司从斯坦福大学Irv Weissman教授的实验室中分离出来，专注于免疫肿瘤学。Weissman和Ravi Majeti博士是Forty Seven的联合创始人，该公司于2020年被Gilead Sciences收购。该公司的主要项目针对表面蛋白CD24，这是一种被许多癌症（包括卵巢癌和乳腺癌）征用的“不要吃我”信号，以避免被肿瘤内巨噬细胞检测和清除” Continue reading at the original source, linked here.
Jiangsu Hengrui inks deal with One Bio for ex-China rights to SHR-1905
Jiangsu Hengrui Pharmaceuticals has out-licensed global rights, excluding China, for its anti-TSLP monoclonal antibody SHR-1905 to One Bio.
Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced today that its innovative TROP2-ADC (SKB264, also known as MK-2870) met the primary endpoint in the randomized, controlled, open-label, multi-center Phase III clinical trial of SKB264 for injection versus investigator selected regimens in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC) who have failed second-line or above prior standard of care.
Diamond Equity Research Initiates Coverage on YS Biopharma Co., Ltd. (NASDAQ: YS)
Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of YS Biopharma Co., Ltd. (NASDAQ: YS).
Novo Holdings participates in $290m strategic financing of Sangon Biotech
Novo Holdings, a leading international life science investor, today announced it has participated in a $290 million (USD) strategic financing round of Sangon Biotech.
Pfizer faces whistleblower lawsuit from former compliance manager who says he flagged possible fraud in China
Frank Han, the former director of global compliance analytics at Pfizer, has filed a civil complaint against the drugmaker.
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy
Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON).
Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis
Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, today announced the successful enrollment of the first patient in the phase 3 clinical study for MH004 Cream targeting mild to moderate atopic dermatitis. This achievement marks a significant milestone in the pursuit of providing effective and innovative treatment options for patients suffering from this prevalent skin condition.
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
Innovent announced that China's National Medical Products Administration (NMPA) has approved SINTBILO® (tafolecimab injection, anti-PCSK9 monoclonal antibody) for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia.
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with Eyenovia, Inc.
